Molecular mechanisms of collagen isotype-specific modulation of smooth muscle cell phenotype

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 2, 2009, Pages 225-231

  Orr, A Wayne ^a   Lee, Monica Y ^c,d   Lemmon, Julia A ^c,e   Yurdagul Jr , Arif ^a   Gomez, Maria F ^b   Schoppee Bortz, Pamela D ^c   Wamhoff, Brian R ^c,d,e  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF VIRGINIA   (United States)

^d University of Virginia   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Differentiation; Inflammation; Matrix; NFAT; Transcription

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOCARDIN; MYOSIN HEAVY CHAIN; SCLEROPROTEIN; SMOOTH MUSCLE ACTIN; VASCULAR CELL ADHESION MOLECULE 1; CALCINEURIN; ISOPROTEIN; MESSENGER RNA; MUSCLE PROTEIN; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; BINDING SITE; DISEASE COURSE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC TRANSCRIPTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; ANIMAL; AORTA; CELL CULTURE; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; SERUM RESPONSIVE ELEMENT; SIGNAL TRANSDUCTION; TIME; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; ATHEROSCLEROSIS; CALCINEURIN; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN TYPE I; COLLAGEN TYPE IV; GENE EXPRESSION REGULATION; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NFATC TRANSCRIPTION FACTORS; PHENOTYPE; PROTEIN ISOFORMS; RATS; RNA, MESSENGER; SERUM RESPONSE ELEMENT; SERUM RESPONSE FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 59449088249     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.178749     Document Type: Article

References (51)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-2753.
2. Ross R. Atherosclerosis-an inflammatory disease. [see comment]. N Engl J Med. 1999;340:115-126.
3. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801.
4. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75:487-517.
5. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
6. Libby P, Li H. Vascular cell adhesion molecule-1 and smooth muscle cell activation during atherogenesis. J Clin Invest. 1993;92:538-539.
7. Schwartz MA. Integrin signaling revisited. Trends in Cell Biology. 2001;11:466-470.
8. Barnes MJ, Farndale RW. Collagens and atherosclerosis. Exp Gerontol. 1999;34:513-525.
9. Moiseeva EP. Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc Res. 2001;52:372-386.
10. Mawatari K, Liu B, Kent KC. Activation of integrin receptors is required for growth factor-induced smooth muscle cell dysfunction. J Vasc Surg. 2000;31:375-381.
11. Kappert K, Blaschke F, Meehan WP, Kawano H, Grill M, Reck E, Hsueh WA, Law RE, Graf K. Integrins alphavbeta3 and alphavbeta5 mediate VSMC migration and are elevated during neointima formation in the rat aorta. Basic Res Cardiol. 2001;96:42-49.
12. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 1996;87:1069-1078.
13. Yamamoto M, Yamamoto K, Noumura T. Type I collagen promotes modulation of cultured rabbit arterial smooth muscle cells from a contractile to a synthetic phenotype. Exp Cell Res. 1993;204:121-129.
14. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
15. Regan CP, Adam PJ, Madsen CS, Owens GK. Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. J Clin Invest. 2000;106:1139-1147.
16. Wamhoff BR, Hoofnagle MH, Burns A, Sinha S, McDonald OG, Owens GK. A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res. 2004;95:981-988.
17. McDonald OG, Owens GK. Programming smooth muscle plasticity with chromatin dynamics. Circ Res. 2007;100:1428-1441.
18. Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol. 2003;35:577-593.
19. Yoshida T, Sinha S, Dandre F, Wamhoff BR, Hoofnagle MH, Kremer BE, Wang DZ, Olson EN, Owens GK. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ Res. 2003;92:856-864.
20. Chen J, Kitchen CM, Streb JW, Miano JM. Myocardin: a component of a molecular switch for smooth muscle differentiation. J Mol Cell Cardiol. 2002;34:1345-1356.
21. Wang DZ, Olson EN. Control of smooth muscle development by the myocardin family of transcriptional coactivators. Curr Opin Genet Dev. 2004;14:558-566.
22. Pidkovka NA, Cherepanova OA, Yoshida T, Alexander MR, Deaton RA, Thomas JA, Leitinger N, Owens GK. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ Res. 2007;101:792-801.
23. Wamhoff BR, Macdonald T, Lynch KR, Owens GK. Differential regulation of smooth muscle phenotype by sphingosine-1-phosphate receptors in vitro and in response to vascular injury. Arterioscler Thromb Vasc Biol. In press.
24. McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest. 2006;116:36-48.
25. Wamhoff BR, Bowles DK, McDonald OG, Sinha S, Somlyo AP, Somlyo AV, Owens GK. L-type voltage-gated Ca2+ channels modulate expression of smooth muscle differentiation marker genes via a rho kinase/myocardin/SRF-dependent mechanism. Circ Res. 2004;95:406-414.
26. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:812-819.
27. Minami T, Miura M, Aird WC, Kodama T. Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium. J Biol Chem. 2006;281:20503-20520.
28. Lee M, Park J. Regulation of NFAT activation: a potential therapeutic target for immunosuppression. Mol Cells. 2006;22:1-7.
29. Nilsson LM, Sun ZW, Nilsson J, Nordstrom I, Chen YW, Molkentin JD, Wide-Swensson D, Hellstrand P, Lydrup ML, Gomez MF. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol. 2007;292:C1167-C1178.
30. Creemers EE, Sutherland LB, McAnally J, Richardson JA, Olson EN. Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins during cardiovascular development. Development. 2006;133:4245-4256.
31. Klekotka PA, Santoro SA, Zutter MM. alpha 2 integrin subunit cytoplasmic domain-dependent cellular migration requires p38 MAPK. J Biol Chem. 2001;276:9503-9511.
32. Hernandez-Torres F, Martinez-Fernandez S, Zuluaga S, Nebreda A, Porras A, Aranega AE, Navarro F. A role for p38alpha mitogen-activated protein kinase in embryonic cardiac differentiation. FEBS Lett. 2008;582:1025-1031.
33. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007;120:2479-2487.
34. Lara-Pezzi E, Winn N, Paul A, McCullagh K, Slominsky E, Santini MP, Mourkioti F, Sarathchandra P, Fukushima S, Suzuki K, Rosenthal N. A naturally occurring calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration. J Cell Biol. 2007;179:1205-1218.
35. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol. 1997;151:1085-1095.
36. Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, Xu Z, Koshelnick Y, Lipp J, De Martin R, Losert U, Lammer J, Binder BR. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation. 2002;105:633-638.
37. Li H, Cybulsky MI, Gimbrone MA, Jr., Libby P. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol. 1993;143:1551-1559.
38. van Seventer GA, Newman W, Shimizu Y, Nutman TB, Tanaka Y, Horgan KJ, Gopal TV, Ennis E, O'Sullivan D, Grey H, et al. Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J Exp Med. 1991;174:901-913.
39. Damle NK, Klussman K, Linsley PS, Aruffo A. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol. 1992;148:1985-1992.
40. Petersen EJ, Miyoshi T, Yuan Z, Hirohata S, Li JZ, Shi W, Angle JF siRNA silencing reveals role of vascular cell adhesion molecule-1 in vascular smooth muscle cell migration. Atherosclerosis. 2008;98:301-306.
41. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res. 2001;50:556-565.
42. Erl W, Hansson GK, de Martin R, Draude G, Weber KS, Weber C. Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ Res. 1999;84:668-677.
43. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 2006;12:1075-1080.
44. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest. 2006;116:59-69.
45. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001;107:255-264.
46. Pei H, Wang Y, Miyoshi T, Zhang Z, Matsumoto AH, Helm GA, Tellides G, Shi W. Direct evidence for a crucial role of the arterial wall in control of atherosclerosis susceptibility. Circulation. 2006;114:2382-2389.
47. Davis GE. Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem Biophys Res Commun. 1992;182:1025-1031.
48. Pedchenko V, Zent R, Hudson BG. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alphas chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. J Biol Chem. 2004;279:2772-2780.
49. Heino J. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biology. 2000;19:319-323.
50. Skinner MP, Raines EW, Ross R. Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagen-coated membranes. Am J Pathol. 1994;145:1070-1081.
51. Hou G, Vogel WF, Bendeck MP. Tyrosine kinase activity of discoidin domain receptor 1 is necessary for smooth muscle cell migration and matrix metalloproteinase expression. Circ Res. 2002;90:1147-1149.